Biolevate raises €30M for life-sciences agents

Biolevate raised €30 million in Series A funding to scale an agentic platform for scientific and regulatory workflows, which it says can run up to 100,000 agents concurrently. Tech.eu’s funding report says the company claims 16× faster literature reviews, an 80% efficiency gain in regulatory intelligence, and more than a dozen enterprise customers; Biolevate’s platform overview describes governed, source-linked outputs for regulated teams. Operators should file this as a deployment claim, not clinical evidence, and compare its human-oversight premise with the archive’s analysis of AI-assisted drug discovery.